Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda + Lenvima vs Keytruda for first-line cisplatin-ineligible advanced urothelial carcinoma
CTR20200643Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in transitional cell carcinoma (TCC), sponsored by Merck & Co.. Started May 2020; status: terminated.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20200643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200643.